<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214239</url>
  </required_header>
  <id_info>
    <org_study_id>1218.66</org_study_id>
    <nct_id>NCT01214239</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug na√Øve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control</brief_title>
  <official_title>A Randomized, db, Placebo Controlled Parallel Group Efficacy and Safety Study Over 24 Weeks in T2D Patients in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of
      Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of
      treatment in monotherapy in patients with type 2 diabetes and insufficient glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change From Baseline at Week 24</measure>
    <time_frame>Baseline and at week 24</time_frame>
    <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 6</measure>
    <time_frame>Baseline and at week 6</time_frame>
    <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 12</measure>
    <time_frame>Baseline and at week 12</time_frame>
    <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 18</measure>
    <time_frame>Baseline and at week 18</time_frame>
    <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline at Week 24 in the Subset of Chinese Patients</measure>
    <time_frame>Baseline and at week 24</time_frame>
    <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 6</measure>
    <time_frame>Baseline and at week 6</time_frame>
    <description>Means are treatment adjusted for baseline fasting plasma glucose (FPG) and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 12</measure>
    <time_frame>Baseline and at week 12</time_frame>
    <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 18</measure>
    <time_frame>Baseline and at week 18</time_frame>
    <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG Change From Baseline at Week 24</measure>
    <time_frame>Baseline and at week 24</time_frame>
    <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HbA1c &lt; 7.0%</measure>
    <time_frame>baseline and at week 24</time_frame>
    <description>Number of patients with HbA1c &lt; 7.0% at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HbA1c &lt; 7.0% at Week 24 With Baseline HbA1c &gt;= 7.0%.</measure>
    <time_frame>baseline and at week 24</time_frame>
    <description>Number of patients with HbA1c &lt; 7.0% at week 24 with baseline HbA1c &gt;= 7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HbA1c &lt; 6.5%</measure>
    <time_frame>baseline and at week 24</time_frame>
    <description>Number of patients with HbA1c &lt; 6.5% at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HbA1c &lt; 6.5% at Week 24 With Baseline HbA1c &gt;= 6.5%.</measure>
    <time_frame>baseline and at week 24</time_frame>
    <description>Number of patients with HbA1c &lt; 6.5% at week 24 with baseline HbA1c &gt;= 6.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number With HbA1c at Least Lowering 0.5%</measure>
    <time_frame>baseline and at week 24</time_frame>
    <description>Number with HbA1c at least 0.5% lowering from baseline at week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>once a day</description>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female patients with a diagnosis of type 2 diabetes mellitus, either
             treatment naive or treated with one antidiabetic medication. Antidiabetic therapy has
             to be unchanged for 6 weeks prior to the informed consent

          2. Diagnosis of type 2 diabetes prior to informed consent

          3. Glycosylated haemoglobin A1 (HbA1c) at Visit 1a (Screening):

             For patients undergoing wash out of previous medication: HbA1c =7.0to =9.5% For
             patients not undergoing wash-out of previous medication: HbA1c =7.0 to =10.0%

          4. Glycosylated haemoglobin A1 (HbA1c) =7.0 to =10.0% at Visit 2 (Start of Run-in)

          5. Age = 18 and &lt; 80 years at Visit 1a (Screening)

          6. BMI (Body Mass Index) = 45 kg/m2 at Visit 1a (Screening)

          7. Signed and dated written informed consent by date of Visit 1a in accordance with GCP
             and local legislation

        Exclusion criteria:

          1. Myocardial infarction, stroke or TIA within 6 months prior to informed consent

          2. Impaired hepatic function, defined by serum levels of either Alanine
             transaminase(SGPT), Aspartate transaminase(SGOT), or alkaline phosphatase above 3 x
             upper limit of normal (ULN) as determined at Visit 1a

          3. Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an
             overnight fast during wash-out / placebo run-in and confirmed by a second measurement
             (not on the same day)

          4. Known hypersensitivity or allergy to the investigational product or its excipients

          5. Treatment with more than one antidiabetic drug within 6 weeks prior to informed
             consent

          6. Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent

          7. Treatment with Glucagon-like peptide 1(GLP-1) analogues (e.g. exenatide) ,
             Dipeptidyl-Peptidase 4(DPP-IV) inhibitor within 3 months prior to informed consent

          8. Treatment with insulin within 3 months prior to informed consent

          9. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3
             months prior to informed consent

         10. Alcohol abuse within the 3 months prior to informed consent that would interfere with
             trial participation or drug abuse

         11. Participation in another trial with an investigational drug within 2 months prior to
             informed consent

         12. Pre-menopausal women (last menstruation = 1 year prior to informed consent) who:

               -  are nursing or pregnant,

               -  or are of child-bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the study
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include transdermal patch,
                  intra-uterine devices/systems (IUDs/IUSs), oral, implantable or injectable
                  contraceptives, sexual abstinence and vasectomised partner. No exception will be
                  made.

         13. Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent.

         14. Renal failure or renal impairment (serum creatinine =1.5 mg/dl as determined at Visit
             1a)

         15. Dehydration by clinical judgement of the investigator

         16. Unstable or acute congestive heart failure

         17. Acute or chronic metabolic acidosis (present in patient history)

         18. Hereditary galactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.66.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johor Bahru,</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marikina</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.66.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Malaysia</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <results_first_submitted>May 24, 2013</results_first_submitted>
  <results_first_submitted_qc>May 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2013</results_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 608 patients were screened in 19 centres in China, Malaysia,and Philippines.A total of 300 patients were randomised in a 1:2 ratio to receive either placebo (99 patients) or linagliptin 5 mg (201 patients).</recruitment_details>
      <pre_assignment_details>Six week (4 weeks of wash-out period, followed by by a two week open-label placebo run-in period) for patients pre-treated with one oral antidiabetic agent in addition to metformin or two weeks placebo run-in for patients pre-treated with metformin monotherapy</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>Linagliptin 5mg</title>
          <description>Linagliptin 5mg, once daily tablets, oral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99">patients who were randomised and treated with placebo</participants>
                <participants group_id="P2" count="200">patients who were randomised and treated with placebo. 1 patient was not treated then not included</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>patient's private reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>Linagliptin 5mg</title>
          <description>Linagliptin 5mg, once daily tablets, oral</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="299"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="9.3"/>
                    <measurement group_id="B2" value="54.6" spread="10.1"/>
                    <measurement group_id="B3" value="54.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Baseline body mass index (BMI)</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="3.4"/>
                    <measurement group_id="B2" value="25.5" spread="3.3"/>
                    <measurement group_id="B3" value="25.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1c</title>
          <description>Baseline HbA1c</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.09" spread="0.91"/>
                    <measurement group_id="B2" value="7.95" spread="0.89"/>
                    <measurement group_id="B3" value="7.99" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline fasting plasma glucose</title>
          <description>Baseline fasting plasma glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161.4" spread="39.9"/>
                    <measurement group_id="B2" value="151.4" spread="32.4"/>
                    <measurement group_id="B3" value="154.6" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline at Week 24</title>
        <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 24</title>
          <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.10"/>
                    <measurement group_id="O2" value="-0.68" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 6</title>
        <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 6</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 6</title>
          <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.072" spread="0.065"/>
                    <measurement group_id="O2" value="-0.454" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.383</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.527</ci_lower_limit>
            <ci_upper_limit>-0.238</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 12</title>
        <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 12</title>
          <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.108" spread="0.08"/>
                    <measurement group_id="O2" value="-0.609" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.677</ci_lower_limit>
            <ci_upper_limit>-0.323</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 18</title>
        <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 18</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 18</title>
          <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.159" spread="0.087"/>
                    <measurement group_id="O2" value="-0.670" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.512</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.098</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.705</ci_lower_limit>
            <ci_upper_limit>-0.318</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline at Week 24 in the Subset of Chinese Patients</title>
        <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available (in the subset of Chinese patients). Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline at Week 24 in the Subset of Chinese Patients</title>
          <description>Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available (in the subset of Chinese patients). Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>% of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.11"/>
                    <measurement group_id="O2" value="-0.69" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 6</title>
        <description>Means are treatment adjusted for baseline fasting plasma glucose (FPG) and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 6</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 6</title>
          <description>Means are treatment adjusted for baseline fasting plasma glucose (FPG) and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.7"/>
                    <measurement group_id="O2" value="-12.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-11.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.2</ci_lower_limit>
            <ci_upper_limit>-5.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 12</title>
        <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 12</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 12</title>
          <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="3.0"/>
                    <measurement group_id="O2" value="-11.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0086</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-8.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.4</ci_lower_limit>
            <ci_upper_limit>-2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 18</title>
        <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 18</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 18</title>
          <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.4"/>
                    <measurement group_id="O2" value="-10.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0135</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-9.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.0</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FPG Change From Baseline at Week 24</title>
        <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
        <time_frame>Baseline and at week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>FPG Change From Baseline at Week 24</title>
          <description>Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Last observation carried forward (LOCF) was used as the imputation rule.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.4"/>
                    <measurement group_id="O2" value="-8.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-9.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.1</ci_lower_limit>
            <ci_upper_limit>-2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HbA1c &lt; 7.0%</title>
        <description>Number of patients with HbA1c &lt; 7.0% at week 24</description>
        <time_frame>baseline and at week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HbA1c &lt; 7.0%</title>
          <description>Number of patients with HbA1c &lt; 7.0% at week 24</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HbA1c &lt; 7.0% at Week 24 With Baseline HbA1c &gt;= 7.0%.</title>
        <description>Number of patients with HbA1c &lt; 7.0% at week 24 with baseline HbA1c &gt;= 7.0%.</description>
        <time_frame>baseline and at week 24</time_frame>
        <population>This population includes the FAS with baseline HbA1c &gt;= 7.0%. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HbA1c &lt; 7.0% at Week 24 With Baseline HbA1c &gt;= 7.0%.</title>
          <description>Number of patients with HbA1c &lt; 7.0% at week 24 with baseline HbA1c &gt;= 7.0%.</description>
          <population>This population includes the FAS with baseline HbA1c &gt;= 7.0%. Non-completers were considered as failure imputation (NCF).</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison by odds ratio for the patients with a baseline HbA1c &gt;= 7.0%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.552</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.407</ci_lower_limit>
            <ci_upper_limit>4.629</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HbA1c &lt; 6.5%</title>
        <description>Number of patients with HbA1c &lt; 6.5% at week 24</description>
        <time_frame>baseline and at week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HbA1c &lt; 6.5%</title>
          <description>Number of patients with HbA1c &lt; 6.5% at week 24</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HbA1c &lt; 6.5% at Week 24 With Baseline HbA1c &gt;= 6.5%.</title>
        <description>Number of patients with HbA1c &lt; 6.5% at week 24 with baseline HbA1c &gt;= 6.5%.</description>
        <time_frame>baseline and at week 24</time_frame>
        <population>This population includes the FAS with baseline HbA1c &gt;= 6.5%. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HbA1c &lt; 6.5% at Week 24 With Baseline HbA1c &gt;= 6.5%.</title>
          <description>Number of patients with HbA1c &lt; 6.5% at week 24 with baseline HbA1c &gt;= 6.5%.</description>
          <population>This population includes the FAS with baseline HbA1c &gt;= 6.5%. Non-completers were considered as failure imputation (NCF).</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison by odds ratio for the patients with a baseline HbA1c &gt;= 6.5%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2500</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.583</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.724</ci_lower_limit>
            <ci_upper_limit>3.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number With HbA1c at Least Lowering 0.5%</title>
        <description>Number with HbA1c at least 0.5% lowering from baseline at week 24</description>
        <time_frame>baseline and at week 24</time_frame>
        <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Linagliptin 5mg, once daily tablets, oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number With HbA1c at Least Lowering 0.5%</title>
          <description>Number with HbA1c at least 0.5% lowering from baseline at week 24</description>
          <population>The Full Analysis Set (FAS) included all treated and randomised patients with a baseline and at least one on-treatment HbA1c measurement available. Non-completers were considered as failure imputation (NCF).</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.527</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.494</ci_lower_limit>
            <ci_upper_limit>4.276</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Linagliptin 5mg</title>
          <description>Linagliptin 5mg, once daily tablets, oral</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

